CVS Health Corporation $CVS Shares Sold by National Pension Service

National Pension Service lessened its holdings in shares of CVS Health Corporation (NYSE:CVS) by 17.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,320,859 shares of the pharmacy operator’s stock after selling 678,763 shares during the period. National Pension Service’s holdings in CVS Health were worth $263,543,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Alteri Wealth LLC increased its position in shares of CVS Health by 3.2% in the third quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock valued at $316,000 after buying an additional 131 shares in the last quarter. TOWER TRUST & INVESTMENT Co increased its holdings in CVS Health by 0.8% during the 4th quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock valued at $1,247,000 after acquiring an additional 132 shares in the last quarter. Holistic Financial Partners increased its holdings in CVS Health by 4.1% during the 3rd quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock valued at $256,000 after acquiring an additional 133 shares in the last quarter. CYBER HORNET ETFs LLC increased its holdings in CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after acquiring an additional 134 shares in the last quarter. Finally, LS Investment Advisors LLC increased its holdings in CVS Health by 3.9% during the 4th quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock valued at $284,000 after acquiring an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark said it will restore coverage of Eli Lilly’s weight-loss drug Zepbound and add Lilly’s new obesity pill to its standard drug plans, a move that could improve member access and make CVS’s drug formularies more competitive. Article Title
• Positive Sentiment: CVS Health Ventures led a $40 million investment in H1, reinforcing CVS’s push into health-tech and AI-driven provider data accuracy, which could support long-term digital growth initiatives. Article Title
• Positive Sentiment: Aetna launched “Aetna Mental Health On Demand,” giving members faster access to mental-health care and adding another visible example of CVS expanding its integrated care offerings. Article Title
• Positive Sentiment: CVS also expanded its Salesforce partnership to improve call-center service with AI tools, which may lower friction for members and providers and improve operating efficiency. Article Title
• Neutral Sentiment: Several reports focused on CVS’s dividend safety, with commentary suggesting the payout remains covered by cash flow; this is reassuring for income investors, but it is not a direct catalyst. Article Title
• Negative Sentiment: CVS filed suit to challenge Tennessee’s new PBM-pharmacy breakup law, signaling regulatory and legal pressure on part of its business model; however, this is more of a risk factor than an immediate earnings driver. Article Title

CVS Health Stock Up 1.0%

CVS opened at $92.95 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The firm has a market cap of $118.59 billion, a P/E ratio of 40.95, a PEG ratio of 0.90 and a beta of 0.60. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The business’s fifty day simple moving average is $81.71 and its 200 day simple moving average is $79.47.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities research analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

Insiders Place Their Bets

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Corporate insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on CVS. Mizuho raised their target price on shares of CVS Health from $102.00 to $110.00 and gave the company an “outperform” rating in a report on Wednesday, May 20th. JPMorgan Chase & Co. raised their target price on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. DA Davidson raised their target price on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Leerink Partners restated an “outperform” rating and set a $98.00 target price on shares of CVS Health in a report on Thursday, March 5th. Finally, Wells Fargo & Company raised their target price on shares of CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $98.88.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.